The study has proven the viability of this approach by studying in mice the evolution of metastatic colon tumors of human patients
Scientists Determine a mechanism that would allow treating more aggressive tumors Read More »
The mechanism does not activate the reduction of oxygen in the cells of the tumor, contrary to what common drugs, called anti-angiogenic, usually cause
The Centre de Cultura Contemporània of Barcelona (CCCB), with the collaboration of the Bellvitge Biomedical Research Institute (IDIBELL) and the program of Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), organized last 25th June 2019 a conference at the CCCB called “Quantum Technology and Cancer. Research and application in its detection and treatment.” In this interactive
Quantum technology and cancer. Research and application in its detection and treatment Read More »
The white matter structure in the brain reflects music sensitivity, according to a study by the research group on Cognition and Brain Plasticity of the Institute of Neurosciences of the University of Barcelona (UB) and the Bellvitge Biomedical Research Institute (UB-IDIBELL). The study, published in Journal of Neuroscience, shows that white matter connectivity, the tissue
Brain structure determines individual differences regarding music sensitivity Read More »
The company will soon initiate preclinical validation tests of its implantable medical devices
Tractivus raises 431,000 euros and consolidates its growth Read More »
Cognitive-motor and psychiatric profiles of Huntington’s disease show a different pattern of brain alterations
The ‘human molecular genetics’ research group of the Bellvitge Biomedical Research Institute, led by Dr. Virginia Nunes (IDIBELL – UB – CIBERER), has participated in a research study demonstrating that the amino acid transporter LAT2 causes congenital cataracts in both animals and humans. This study, published in Frontiers in Physiology, has discovered that LAT2 ablation causes
La Fundación nace con un acuerdo de colaboración con el IDIBELL (Instituto de Investigación Biomédica de Bellvitge) y el ICO (Institut Català d’Oncología)
Fundación Mey Hofmann, al lado de las mujeres con cáncer de mama Read More »
The Foundation is born with a collaboration agreement with the IDIBELL (Bellvitge Biomedical Research Institute) and the ICO (Catalan Institute of Oncology)
Mey Hofmann Foundation, next to women with breast cancer Read More »
Scientists propose a new way to face this resistance and a first biomarker to predict if it could appear or not
